The 2nd Congress of the EAN includes the following networking programme and special sessions:   Friday, May 27, 2016: EBN Examination.
The UEMS EBN examination will be held one day prior to the congress at Bella Center Copenhagen. The examination… Continue Reading

On March 18th, 2016 the ‘Consensus statement on European Brain Research’ (Morris et al., 2016) has been launched in Brussels at the Brussel office of the European Brain Council. Several organisations related to brain science, including the European Academy of Neurology, participated. The European Brain Council is uniting the European organisations of physicians for Neurology, Psychiatry, Neurosurgery, the scientists for both molecular and systemic Neurosciences and the European patient organisations for neurological and psychiatric diseases (see below 1).

David B. Vodušek (DBV): The EFNR is a multidisciplinary organisation open to any professional with an interest in neurological rehabilitation. Its structure is quite similar to that of the EAN. Can you briefly illustrate how the EFNR operates and works? Leopold Saltuari (LS): The European Federation of NeuroRehabilitation Societies (EFNR) is open to all colleagues interested in the field of neuro-rehabilitation. It was founded in order to create a common platform for the national European societies of neuro-rehabilitation as well as other organizations with similar interests.

As in the previous year, Neuropenews asked EAN committee members, panel chairs, speakers etc. which session one should not miss at the upcoming congress in Copenhagen 2016. Please find their answers below!

Elena Moro (EM): As incoming co-chair of the Scientific Panel “Child Neurology” can you briefly introduce yourself and your main areas of interest to the Neuropenews readers. Lieven Lagae (LL): Currently, I am the president of the European Pediatric Neurology Society (EPNS) which is representing the large majority of pediatric neurologists in Europe. I am a full Professor at the University of Leuven Belgium and Director of the Pediatric Neurology program at the University Hospitals of the University of Leuven Belgium. We offer a comprehensive diagnostic and therapeutic program for all major neurological problems in children.

Elena Moro (EM): As incoming co-chair of the Scientific Panel “Neuro-traumatology” can you briefly introduce yourself and your specific field of expertise to the Neuropenews readers. Oliver Kastrup (OK): I received my training in neurology and psychiatry at the University of Essen-Duisburg including a stint in neuroradiology. I have been holding the post of assistant professor in neurology and senior consultant for twelve years here in Essen. My special interest is rare and inflammatory diseases as well as neuro-traumatology.

Elena Moro (EM): As incoming co-chair of the Scientific Panel “Neuro-oncology” can you briefly introduce yourself and your specific field of expertise to the Neuropenews readers. Stefan Oberndorfer (SO): As a Neurologist, my special field of interest is clinical Neuro-oncology. Presently, I am working as a head of Department for Neurology at the Karl Landsteiner University Clinic of St Pölten in Austria. My main areas of clinical research are brain tumors, tumor associated epilepsy, palliative care in brain tumor patients, spinal metastases, neurotoxicity of anticancer treatment, paraneoplastic neurological syndromes and symptomatic treatment in neuro-oncology.

Dear Readers, We invite you to read the following article recommendations, prepared for you by our Scientific Panels: Dementia and cognitive disorders, Higher cortical functions, Infectious diseases, Movement disorders, Palliative care. Winblad B, Amouyel P, Andrieu S, et al. Defeating… Continue Reading

or April 2016 we have selected: Lublin F, Miller DH, Freedman MS, et al., on behalf of the INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet Neurol, 27 Jan 2016; pii: S0140-6736(15)01314-8. doi: 10.1016/S0140-6736(15)01314-8. Primary progressive multiple sclerosis (PPMS) represents around 10-15% of the clinical forms of MS. Several characteristics differentiate PPMS from the relapse-onset MS, the classical more frequent form: older age at onset, equal prevalence between sexes, less inflammatory component at the MRI, and quicker progression of disability.

Pain - the unpleasant sensory and emotional experience associated with tissue damage - is usually not considered to be a neurological sub-disciplines like for example cerebrovascular diseases, demyelinating disorders, neururomuscular diseases, movement disorders, epilepsy, headache and clinical neurophysiology.

As in the previous years, EAN-RRFS delegate will join the EAN Spring School 2016 and the Regional Teaching courses (RTC) in order to spread information regarding postgraduate education in neurology and relevant opportunities for neurologists in training. This year, our representatives providing the updated information will be Panagiotis Zis (EAN Spring School 2016, May 12-15, 2016 Stare Splavy, Czech Republic), Orsolya Gyorfi (RTC, Kutasi, Georgia, Oct. 6-8, 2016), and Viktoria Papp (RTC, Yekaterinburg, Russia, Nov. 3-5, 2016).